Jazz Pharma's decision to revoke U.S. patent for rival narcolepsy drug

Published Date: 02 Mar 2023

A U.S. court on Friday ordered Jazz Pharmaceuticals to revoke its patents related to its flagship narcolepsy drug Xyrem from the FDA-approved brand name drug after winning a case against Avadel foe CNS Pharmaceuticals.

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Experts Discuss Groundbreaking Advances in EGFR-Mutant Lung Cancer

2.

Obesity linked to subsequent neoplasms in childhood cancer survivors

3.

For older patients with Hodgkin lymphoma, novel regimens produce high response rates.

4.

Month-Long Wait Times Caused by US Physician Shortage.

5.

Momelotinib, a JAK inhibitor, has FDA approval to treat adult myelofibrosis in anemic patients.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot